^
2ms
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. (PubMed, Mol Ther Oncol)
CD33PAN moieties were detected at a higher frequency on human leukemic stem cells, and CD33PAN CAR T cells had greater in vitro efficacy against primary human AML cells. Together, our studies demonstrate improved efficacy with CAR T cells binding CD33 close to the cell membrane, providing the rationale to investigate CD33PAN CAR T cells further toward possible clinical application.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD33 (CD33 Molecule)
|
CD33 expression
|
CD33PAN CAR T
3years
Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy (ASH 2021)
Similar constructs using scFvs from 2 different V-set domain-targeting CD33 antibodies, including hP67.6 (My96; used in gemtuzumab ozogamicin), were generated for comparison. Targeting the membrane proximal domain of CD33 enhances the anti-leukemic potency of CAR T cells. Our data provide the rationale for the further development of CD33 PAN CAR T cells toward clinical testing.
CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule)
|
Mylotarg (gemtuzumab ozogamicin) • CD33PAN CAR T